The venture firm’s “modest” $450 million fund, a lower total than some of its peers recently raised, reflects lessons learned ...

The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a ...

The company is developing treatments to rebalance, rather than suppress, immune function in people with inflammatory ...

N4 Pharma Plc (AIM: N4P), the specialist preclinical stage biotech company announces a new lead programme, N4 101. This orally-delivered inflammation inhibitor for Irritable Bowel Disease (IBD) uses ...

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...

The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...

Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program ...

The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier ...

The collaboration is another vote of confidence in Dewpoint’s biomolecular condensates research, which had already attracted ...

While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to ...

The company reached a deal to divest its third biosimilar this year, selling a copycat version of Amgen’s Neulasta for up to ...

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...